Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the soft tissue sarcoma committee of the children's oncology group

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 6072-6079

  Spunt, Sheri L ^a,g   Smith, Lynette M ^b   Ruymann, Frederick B ^c   Qualman, Stephen J ^c   Donaldson, Sarah S ^d   Rodeberg, David A ^e   Anderson, James R ^b   Crist, William M ^f   Link, Michael P ^d  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e Mayo Eugenio Litta Children's Hospital   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; NARCOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ANEMIA; ANUS DISEASE; APPENDICITIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DESQUAMATION; DIFFUSE ALVEOLAR DAMAGE; DIGESTIVE SYSTEM INFLAMMATION; DRUG FATALITY; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFANT; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG ALVEOLUS; LUNG INJURY; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; ORGANIZATION; OUTCOMES RESEARCH; PANCREATITIS; PERIANAL DESQUAMATION; PILOT STUDY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RISK ASSESSMENT; SCHOOL CHILD; SENSORY DYSFUNCTION; SEPTIC SHOCK; STOMATITIS; SUDDEN DEATH; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INFANT; MALE; MAXIMUM TOLERATED DOSE; RHABDOMYOSARCOMA; RISK; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 4644335909     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0654     Document Type: Article

References (37)

1. Ries LA, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute; 1999. p. 2-3.
2. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study. I. A final report. Cancer (Phila.) 1988;61(2): 209-20.
3. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer (Phila.) 1993;71(5):1904-22.
4. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13(3):610-30.
5. Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69(4):585-94.
6. Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with hematopoietic stem cell support for solid tumors. Br J Cancer 2001;85(4):484-9.
7. Ozkaynak MF, Nolta J, Parkman R. In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide. Cancer Res 1990;50(15):1455-8.
8. Griswold DP Jr, Trader MW, Frei E 3rd, et al. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. Cancer Res 1987;47(9):2323-7.
9. Wexler LH, Weaver-McClure L, Steinberg SM, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 1996;14(3):901-10.
10. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12(12):2607-13.
11. Carpenter PA, White L, McCowage GB, et al. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Cancer (Phila.) 1997;80(3):489-96.
12. Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000;18(12):2427-34.
13. Delepine N, Delepine G, Cornille H, et al. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. J Chemother 1997;9(5):352-63.
14. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991;9(6):1050-8.
15. Lagarde P, Bonichon F, Eghbali H, et al. Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Br J Cancer 1989;59(4):645-9.
16. Schneeweiss A, Hensel M, Sinn P, et al. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. Ann Oncol 2002;13(5):679-88.
17. Tjan-Heijnen VC, Wagener DJ, Postmus PE. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002;13(10):1519-30.
18. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998;1(6): 550-61.
19. Boue DR, Parham DM, Webber B, et al. Clinicopathologic study of ectomesenchymomas from Intergroup Rhabdomyosarcoma Study Groups III and IV. Pediatr Dev Pathol 2000;3(3):290-300.
20. Maurer HM. The Intergroup Rhabdomyosarcoma Study (NIH): objectives and clinical staging classification. J Pediatr Surg 1975;10(6): 977-8.
21. Lawrence W Jr, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Cancer (Phila.) 1997;80(6): 1165-70.
22. Ruymann FB, Vietti T, Gehan E, et al. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol 1995;17(4):331-7.
23. Greenwood M. A report on the natural duration of cancer. London: H.M.S.O.; 1926. p. 1-26.
24. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980. p. 169.
25. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21(18):3423-30.
26. Crist WM, Andersen JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19(12):3091-102.
27. Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18(5):947-55.
28. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001;19(5):1405-13.
29. Heyn R, Haeberlen V, Newton WA, et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. J Clin Oncol 1993;11(2):262-70.
30. Spunt SL, Meza JL, Anderson JR, et al. Second malignant neoplasms (SMN) in children treated for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies (IRS) I-IV. Proc Am Soc Clin Oncol 2001;20:369a.
31. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the English literature. Cancer (Phila.) 1979;43(6):2223-6.
32. Nieto Y, Cagnoni PJ, Bearman SI, Shpall ES, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 2000;6(2A):198-203.
33. Ando M, Yokozawa T, Sawada J, et al. Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2000;25(2): 185-9.
34. Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001;23(4):225-33.
35. Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2001;19(1):213-9.
36. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17(9):2796-803.
37. Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001;23(5):272-6.